SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-027453
Filing Date
2022-05-17
Accepted
2022-05-17 08:32:41
Documents
13
Period of Report
2022-05-17

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea160076-6k_altamira.htm 6-K 12796
2 SHAREHOLDER LETTER DATED SPRING 2022 ea160076ex99-1_altamira.htm EX-99.1 40536
3 GRAPHIC ex99-1_001.jpg GRAPHIC 28647
4 GRAPHIC ex99-1_002.jpg GRAPHIC 9319
5 GRAPHIC ex99-1_003.jpg GRAPHIC 47117
6 GRAPHIC ex99-1_004.jpg GRAPHIC 58533
7 GRAPHIC ex99-1_005.jpg GRAPHIC 12424
8 GRAPHIC ex99-1_006.jpg GRAPHIC 18238
9 GRAPHIC ex99-1_007.jpg GRAPHIC 35270
10 GRAPHIC ex99-1_008.jpg GRAPHIC 15124
11 GRAPHIC ex99-1_009.jpg GRAPHIC 28275
12 GRAPHIC ex99-1_010.jpg GRAPHIC 12160
13 GRAPHIC ex99-1_011.jpg GRAPHIC 41542
  Complete submission text file 0001213900-22-027453.txt   478555
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM 11 D0 00000
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM 11 D0 00000 41 (0) 41 729 71 94
Altamira Therapeutics Ltd. (Filer) CIK: 0001601936 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36582 | Film No.: 22932342
SIC: 2834 Pharmaceutical Preparations